Search research articles
Contact Us
Filters
Showing results (631-640 of 742) with videos related to
Page
of 75
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 9, 2023
Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC
Ross A Soo, Jean-François Martini, Anthonie J van der Wekken, et al.
The New England Journal of Medicine
|
June 7, 2017
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
Solange Peters, D Ross Camidge, Alice T Shaw, et al.
British Journal of Cancer
|
July 1, 2015
Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer
P A Jänne, I Smith, G McWalter, et al.
Multiple Sclerosis and Related Disorders
|
June 30, 2019
Response heterogeneity to home-based restorative cognitive rehabilitation in multiple sclerosis: An exploratory study
Tom A Fuchs, Stefano Ziccardi, Michael G Dwyer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 30, 2026
Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small cell lung cancer: 7-year update from the phase 3 CROWN study
A T Shaw, B J Solomon, E Felip, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 28, 2015
Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases
Daniel B Costa, Alice T Shaw, Sai-Hong I Ou, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 29, 2019
Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC
Makoto Nishio, Enriqueta Felip, Sergey Orlov, et al.
The Lancet. Oncology
|
November 1, 2019
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial
Alice T Shaw, Benjamin J Solomon, Rita Chiari, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 24, 2019
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study
D Ross Camidge, Rafal Dziadziuszko, Solange Peters, et al.
Clinical Pharmacokinetics
|
December 11, 2023
Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer
Joseph Chen, Alessandra Bearz, Dong-Wan Kim, et al.
Page
of 75
Search research articles
Search
Showing results (631-640 of 742) with videos related to
Sort By:
Page
of 75
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 9, 2023
Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC
Ross A Soo, Jean-François Martini, Anthonie J van der Wekken, et al.
The New England Journal of Medicine
|
June 7, 2017
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
Solange Peters, D Ross Camidge, Alice T Shaw, et al.
British Journal of Cancer
|
July 1, 2015
Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer
P A Jänne, I Smith, G McWalter, et al.
Multiple Sclerosis and Related Disorders
|
June 30, 2019
Response heterogeneity to home-based restorative cognitive rehabilitation in multiple sclerosis: An exploratory study
Tom A Fuchs, Stefano Ziccardi, Michael G Dwyer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 30, 2026
Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small cell lung cancer: 7-year update from the phase 3 CROWN study
A T Shaw, B J Solomon, E Felip, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 28, 2015
Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases
Daniel B Costa, Alice T Shaw, Sai-Hong I Ou, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 29, 2019
Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC
Makoto Nishio, Enriqueta Felip, Sergey Orlov, et al.
The Lancet. Oncology
|
November 1, 2019
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial
Alice T Shaw, Benjamin J Solomon, Rita Chiari, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 24, 2019
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study
D Ross Camidge, Rafal Dziadziuszko, Solange Peters, et al.
Clinical Pharmacokinetics
|
December 11, 2023
Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer
Joseph Chen, Alessandra Bearz, Dong-Wan Kim, et al.
Page
of 75